ERBB2 and breast carcinoma: Gene expression profiling and immunohistochemistry analysis of 53 HER2-positive breast cancer patients indicated that trastuzumab-sensitive tumors expressed significantly higher levels of chemokines involved in immune cell recruitment, with higher infiltration of T cells and monocytes (25).